After participating in this educational activity, attendees should be able to:
1|Define general principles of USP <797> and interpret relevant updates to these regulations
2|Identify how complying with USP <797> can prevent medication errors associated with contamination
3|Discuss the Board of Pharmacy’s proposed regulations related to 247 CMR 17 (sterile compounding) and 247 CMR 18 (non-sterile compounding).
4|Describe examples of deviations from USP <797> associated with adverse events related to CSPs.
Ashley Iacoviello, PharmD
PGY2 HSPAL Pharmacy Resident
Baystate Medical Center 
Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education (CE) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options. Any relevant financial relationships are mitigated prior to the educational activity.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 


Accreditation Statement
In support of improving patient care, Baystate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Baystate Health designates this activity for a maximum of 1.0 contact hours (s) for pharmacists. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. 


Session date: 
03/04/2024 - 2:00pm to 3:00pm EST
United States
  • 1.00 ACPE Contact Hours
  • 1.00 BCIPE Instructional Hours

Please login or register to take this course.